This article is more than 5 years old. Information may no longer be current.

NICE recommends melanoma therapy after GSK agrees to offer at discounted price

The United Kingdom’s National Institute for Health and Care Excellence published its final appraisal determination recommending Tafinlar to treat unresectable or metastatic BRAF V600 mutation-positive melanoma.

In the guidance, NICE stated it would recommend Tafinlar (dabrafenib, GlaxoSmithKline) only under the stipulation that the company provides the drug at a discount agreed upon in the patient access scheme.

GlaxoSmithKline has agreed to a patient access discount; however, the scope of the discount is commercial in confidence, according to the appraisal, and was not disclosed.

Key evidence of the drug’s effectiveness came from the BREAK-3 trial, an international, multicenter, randomized, open-label, active-controlled trial comparing dabrafenib with dacarbazine in patients with previously untreated, unresectable, advanced or metastatic BRAF V600 mutation-positive melanoma.